Program
BTK Inhibitor HMPL-760
Also written as “HMPL-760”, “HMPL-760 planned dose 1” and “HMPL-760 planned dose 2”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell · Lymphoma, B-Cell, Marginal Zone, led by HUTCHMED.
Furthest: phase 3, since Jan 28, 20265 company-led studies, 1 open or runningNext primary completion: Apr 30, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 51 open or running | phase 3since Jan 28, 2026 | Nov 19, 2021 | Apr 30, 2028phase 3 · NCT07409428 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2021First study: phase 1 study in Lymphoma, B-Cell, Marginal ZoneFirst studyNCT05176691 · United States, Australia, France and more
- Dec 10, 2021Phase 1 study in Lymphoma, B-CellNCT05190068 · 89 enrolled · China
- Sep 8, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06601504 · 61 enrolled · China
- Jan 28, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffusePhase 3 reachedNCT07409428 · 240 planned · China
- Jun 8, 2026Phase 1 study in Healthy ParticipantsNCT07643272 · 24 enrolled · China
Ahead
- Apr 30, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07409428
TargetBeta
BTK →read by rule
“A third-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07643272Healthy Participants · China | 1 | Completed | Jul 31, 2026 | 24 |
| NCT07409428Lymphoma, Large B-Cell, Diffuse · China | 3 | Recruiting | Apr 30, 2028 | 240 |
| NCT06601504Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | May 23, 2026 | 61 |
| NCT05190068Lymphoma, B-Cell · China | 1 | Completed | Jan 27, 2025 | 89 |
| NCT05176691Lymphoma, B-Cell, Marginal Zone · United States, Australia, France and more | 1 | Withdrawn | Nov 16, 2022 | 0 |
How it is read
Names in the registry
- “HMPL-760”, 4 entries
- “HMPL-760 planned dose 1”, 1 entry
- “HMPL-760 planned dose 2”, 1 entry
- “Rabeprazole and HMPL-760”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lymphoma, B-Cell, 1 study
- Lymphoma, B-Cell, Marginal Zone, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.